Orforglipron
0.5mg x 25 tablets
Oral tirzepatide tablets formulated for sublingual or enteric research applications investigating non-injectable delivery of dual incretin receptor agonists. Oral peptide delivery presents significant bioavailability challenges due to enzymatic degradation and poor intestinal absorption. Research into permeation enhancers such as SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) — successfully employed in oral semaglutide (Rybelsus) — informs ongoing oral tirzepatide development strategies.
Pricing
Mechanism of Action
Same dual GIP/GLP-1 receptor agonism as injectable tirzepatide. Oral bioavailability is substantially lower than subcutaneous administration, with absorption kinetics dependent on formulation strategy, gastric pH, and co-administration with permeation enhancers.
Properties
Molecular Weight
4813.45 Da
Storage
Store at room temperature in a cool, dry place. Protect from moisture.
Research Applications
References & Citations
(2)PIONEER 1: Randomized Clinical Trial of Oral Semaglutide Monotherapy
Aroda VR, Rosenstock J, Terauchi Y, et al.
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
Buckley ST, Bækdal TA, Vegge A, et al.
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.